SubsidieMeestersAddressing malnutrition and metabolic health in non-communicable diseases through precision Nutrition: impact in quality of life and prognosis of lung cancer patients.
MENTORING aims to improve the nutritional and metabolic health of lung cancer patients through personalized dietary plans based on multi-omics approaches, enhancing quality of life and treatment outcomes.
Projectdetails
Introduction
Malnutrition represents a major burden for a large part of the population and, in particular, for vulnerable population groups like lung cancer patients. Lung cancer is a global health crisis, with over 2.2 million new cases in 2020 and profound societal and economic impacts.
Impact on Patients
Lung cancer patients suffer from:
- Reduced quality of life
- Psychological distress
- Comorbidities
- The challenges of frequent treatments
- Malnutrition and metabolic complications
Project Overview
MENTORING seeks to enhance patients' nutritional and metabolic statuses by targeting deficiencies in macro- and micronutrients and restoring the microbiome and glycomic health profiles. This will contribute to improving the overall quality of life of lung cancer patients, increasing treatment efficacy, and potentially enhancing their survival rates.
Methodology
By combining various assessments and analyses, we will develop holistic models able to predict individual responses to personalised dietary plans considering multiple nutritional and metabolic outcomes. The components include:
- Dietary assessment
- Nutritional and clinical biomarkers
- Immune-inflammatory signatures
- Anthropometry
- Genetics
- Glycomics
- Lung and gut microbiome
- Food-related metabolomics
Precision Nutrition Approach
This precision nutrition approach will play a critical role in lung cancer care by customising dietary guidance based on an individual's genetic makeup, nutritional assessment, and health status to reduce cancer progression and increase quality of life.
Broader Application
This collaborative effort is tailored to the specific needs of lung cancer patients, but it has been built in order to make it easily translatable to any other vulnerable population suffering from malnutrition or metabolic impairments.
Ultimate Goal
The ultimate goal of MENTORING is to enhance patients' nutritional and metabolic statuses by using validated multi-omics approaches, potentially transforming the healthcare landscape.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 4.031.666 |
| Totale projectbegroting | € 4.031.666 |
Tijdlijn
| Startdatum | 1-9-2024 |
| Einddatum | 31-8-2028 |
| Subsidiejaar | 2024 |
Partners & Locaties
Projectpartners
- FUNDACION IMDEA ALIMENTACIONpenvoerder
- DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG
- I3S - INSTITUTO DE INVESTIGACAO E INOVACAO EM SAUDE DA UNIVERSIDADE DO PORTO
- UNIVERSITA DEGLI STUDI DI PARMA
- MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV
Land(en)
Vergelijkbare projecten binnen EIC Pathfinder
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Precision Nutrition to optimize immune response for metabolic healthNUTRIMMUNE investigates the impact of precision nutrition on immune responses in obesity-related NCDs, aiming to establish dietary recommendations through multi-omics analysis and intervention studies. | EIC Pathfinder | € 4.318.432 | 2024 | Details |
Bone Marrow-on-Chip as smart sensor of lung cancer relapseBuonMarrow aims to develop an innovative in vitro device using bone marrow mesenchymal stromal cells to early detect lung cancer relapse, enhancing personalized treatment and patient survival. | EIC Pathfinder | € 2.999.835 | 2024 | Details |
Precision Nutrition to optimize immune response for metabolic health
NUTRIMMUNE investigates the impact of precision nutrition on immune responses in obesity-related NCDs, aiming to establish dietary recommendations through multi-omics analysis and intervention studies.
Bone Marrow-on-Chip as smart sensor of lung cancer relapse
BuonMarrow aims to develop an innovative in vitro device using bone marrow mesenchymal stromal cells to early detect lung cancer relapse, enhancing personalized treatment and patient survival.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Setting the optimal balance between metabolite supplementation and deprivation in cancer therapyThis project aims to combine targeted metabolite supplementation with global nutrient restriction to reprogram tumor metabolism, enhance treatment response, and improve survival in advanced triple-negative breast cancer patients. | ERC Starting... | € 1.499.250 | 2023 | Details |
Lifetime Metabolomics for Paediatric Liver Cancer Detection and Therapy Assessment Using Organ-on-Chip PlatformsLIFETIME aims to develop a scalable platform for lifetime metabolomics to enhance early diagnosis and treatment of hepatoblastoma through advanced profiling and tracking of metabolic changes. | ERC Starting... | € 2.499.318 | 2025 | Details |
Actionable metabolite supplements to improve treatment response in pancreatic cancerThe ACT-PC project aims to preclinically validate microbiota-derived metabolites to enhance chemotherapy efficacy and anti-tumor immunity in metastatic pancreatic cancer patients. | ERC Proof of... | € 150.000 | 2024 | Details |
Early Multi-Omic Cancer Assessment: eMOCAThis project aims to identify novel microbial biomarkers for lung squamous cell cancer using non-invasive exhaled breath condensate and multi-omic analyses to improve diagnosis and treatment. | ERC Starting... | € 1.874.336 | 2025 | Details |
Generating mRNA-HNF4a-Lipid nanoparticles for curing pancreatic cancer-associated cachexia (CAC) in identified patients at riskThis project aims to develop and test liver-specific mRNA therapies targeting HNF4a to prevent or alleviate cancer-associated cachexia in pancreatic cancer patients identified by a novel liver score. | ERC Proof of... | € 150.000 | 2023 | Details |
Setting the optimal balance between metabolite supplementation and deprivation in cancer therapy
This project aims to combine targeted metabolite supplementation with global nutrient restriction to reprogram tumor metabolism, enhance treatment response, and improve survival in advanced triple-negative breast cancer patients.
Lifetime Metabolomics for Paediatric Liver Cancer Detection and Therapy Assessment Using Organ-on-Chip Platforms
LIFETIME aims to develop a scalable platform for lifetime metabolomics to enhance early diagnosis and treatment of hepatoblastoma through advanced profiling and tracking of metabolic changes.
Actionable metabolite supplements to improve treatment response in pancreatic cancer
The ACT-PC project aims to preclinically validate microbiota-derived metabolites to enhance chemotherapy efficacy and anti-tumor immunity in metastatic pancreatic cancer patients.
Early Multi-Omic Cancer Assessment: eMOCA
This project aims to identify novel microbial biomarkers for lung squamous cell cancer using non-invasive exhaled breath condensate and multi-omic analyses to improve diagnosis and treatment.
Generating mRNA-HNF4a-Lipid nanoparticles for curing pancreatic cancer-associated cachexia (CAC) in identified patients at risk
This project aims to develop and test liver-specific mRNA therapies targeting HNF4a to prevent or alleviate cancer-associated cachexia in pancreatic cancer patients identified by a novel liver score.